🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Stocks To Watch Ahead Of GOP Healthcare Vote

Published 05/04/2017, 12:51 AM
Updated 07/09/2023, 06:31 AM
CI
-
ELV
-
AET
-
HUM
-
UNH
-
XBI
-
IHI
-

After seven long years of promising to repeal President Obama’s landmark Affordable Care Act, House Republicans finally think that they have enough votes to pass their replacement bill. Representatives are scheduled to vote on the new American Health Care Act on Thursday following several last-minute changes that convinced key moderates and conservatives to support it.

The House vote will likely come down to the wire, and it’s even more likely that the Senate makes key revisions to the bill, but getting the law out of this chamber of Congress would be a clear political victory for Republican leadership and the Trump administration.

Although some pundits expected the GOP to delay its healthcare reform after the original version of the AHCA was canned, the current iteration of the bill garnered centrist and right-wing support relatively quickly.

The GOP’s new plan would eliminate Obamacare subsidies—which are based on income and cost of coverage in their area—and replace them with refundable tax credits based mainly on age. The credits would be worth around $2,000 for those in their 20s to $4,000 for those in their 60s. Credits for people making more than $75,000 would begin to taper our, while people making more than $215,000 would not be eligible for the credits at all.

The AHCA would also do away with the individual and employer mandates, two staples of Obamacare. The individual mandate requires that people have a health insurance plan or face a tax, and the employer mandate requires companies with more than 50 employees to offer an affordable plan to their full-time workers.

These mandates would be replaced by continuous coverage requirements, which levy surcharges on the premiums of those who let their coverage lapse for a certain amount of time. An amendment to the bill now allows states to seek waivers that would replace these requirements with one that allows insurance companies to charge people who had a coverage lapse based on their health.

Critics of the new law claim that the state waiver process weakens coverage for those with pre-existing conditions. While Obamacare absolutely bars any insurer from denying coverage based on a pre-existing condition, the new law allows states to seek waivers that could allow insurance companies to set premiums based on one’s medical background. States would also be able to apply for waivers that would allow insurers to sell plans that don’t include benefits mandated by Obamacare.

Another point of controversy is the plan’s overhaul of Medicaid. The law includes several major changes to Medicaid, including a general shift in responsibility from the federal government to the states. This would likely result in less overall funding for the program, which could result in coverage rollbacks.

A Congressional Budget Office study projects that the AHCA would cut the federal government’s Medicaid spending by 25% by 2026. The CBO also said that the new law would result in 24 million more uninsured people by that year.

So how should investors approach today’s monumental vote? Well, like with anything that brings uncertainty into play, it’s best to approach with caution.

Of course, the most important stocks to watch will be the massive insurance companies, including UnitedHealth (NYSE:UNH) , Anthem (NYSE:ANTM) , Humana (NYSE:HUM) , Aetna (NYSE:AET) , and Cigna (NYSE:CI) .

If you glance back at their historical prices, these stocks didn’t have a massive immediate reaction to the passage of Obamacare in March 2010, but they have all been climbing higher since. In fact, insurers are hitting new highs despite their struggles to profit on Obamacare enrollees.

Investors should also keep an eye on the major health-related ETFs. Those that could see an effect from today’s vote include the iShares U.S. Healthcare Providers ETF IHF, iShares U.S. Medical Devices ETF (MT:IHI) , iShares Nasdaq Biotechnology ETF IBB, SPDR S&P Biotech (MX:XBI) ETF XBI, and the Health Care Select Sector SPDR Fund XLV.

All of these industries will be impacted, as the GOP plan has wide-ranging repercussions for overall access to care, as well as taxes imposed on companies and consumers. However, the same could be said about Obamacare, and historical price data shows that these tickers were all relatively flat during the week that the law passed.

Investors will likely display some sort of initial reaction, but the market could be hesitant regardless of whether the vote passes or not. As mentioned, the Senate will likely make changes, and there seems to be a certain lingering uncertainty about how the AHCA will look in practice—as there also was with Obamacare.

Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>



SPDR-HLTH CR (XLV): ETF Research Reports

ISHARES NDQ BIO (IBB): ETF Research Reports

ISHARS-US H C P (IHF): ETF Research Reports

ISHARS-US MED D (IHI): ETF Research Reports

SPDR-SP BIOTECH (XBI): ETF Research Reports

Cigna Corporation (CI): Free Stock Analysis Report

Aetna Inc. (AET): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.